Pharmacology

Study in JAMA: Antenatal corticosteroids don't impact neurodevelopment in late preterm children aged 6 years and up.

The biosimilar to ustekinumab is approved for patients 6 years and up, and is expected to be marketed on or after February 21, 2025.

Abeona's pz-cel is up for indicated use to treat patients with recessive dystrophic epidermolysis bullosa.

IXINITY is now approved to treat all patients with the hemophilia B to help control bleeding episodes, as well as reduce the frequency of them.

Understand how to naviate the current shortage of pediatric ADHD medications.

Investigators concluded that pharmacists at the pediatric HSSP performed clinical interventions beyond their daily clinical and operational activities, based on results from a study presented at the Health-System Pharmacists Midyear Clinical Meeting & Exhibition held in Anaheim, California, from December 3, 2023, to December 7, 2023.

A sneak peek at some of the most exciting sessions at this year's American Academy of Pediatrics national conference.

From 2006 to 2019, psychotropic medication use for those with type 1 diabetes (T1D) increased, leading investigators to call for risk-benefit studies, further evaluating effectiveness and improved diabetes care in this population.

A look at recent approvals and promising clinical trials for future vaccines.

Numerous tools, technology platforms, and interventions have been developed to help teens with the difficult emotional and physical weight of managing the disease.

GLP-1 receptor agonists, used to treat diabetes, are now also being used for obesity in children and adolescents.

As children get set to head into the sun, grass, and water, now is the perfect time to remind patients and parents about best practices, treatments, and preventive measures.

Manufacturers, hospitals, and clinicians are working quickly to address the shortages of this crucial inhalation solution.

At the 2023 Pediatric Academic Societies meeting, a presentation exploring how pediatric clinicians can best use AI in their research.

Results show a high level of adherence to hydroxyurea medication is essential for lowering the incidence of negative clinical outcomes like VOCs and acute chest syndrome in children with sickle cell anemia.

The introduction of novel biologic agents has revolutionized the treatment of the disease in recent years.